More Life Sciences Opportunities Mean Greater Competition
With the continued rush for life sciences companies to produce a COVID-19 vaccine and growing investor interest in life sciences overall, it’s no wonder that the industry is seeing greater interest from fund managers and private equity firms.
What was once a realm for venture capital groups has rapidly expanded as major players close new funds and launch new platforms. New deals are increasing as companies seek to acquire life sciences companies to gain entry into this extremely competitive space.
In a new piece over at FundFire, WilliamsMarston Managing Director Michael Donoso weighs in on the competition and opportunities in the life sciences industry.